The Rollings Cancer Center (HCC) is directed by Andrew S. Kraft, MD (Director) with the assistance of Anthony J. Alberg, PhD, MPH (Associate Director of Cancer Prevention &Control);Daniel J. Fernandes, PhD (Associate Director of Translational Research);Marvella E. Ford, PhD (Associate Director of Cancer Disparities);Yusuf A. Hannun, MD (Associate Director of Basic Sciences);Anita L. Harrison, MPA (Associate Director of Administration);Carolyn E. Reed, MD (Associate Director of Medical Affairs);Steven A. Rosenzweig, PhD (Assistant Director of Shared Resources);and Melanie B. Thomas, MD (Associate Director of Clinical Investigations). These experienced individuals are organized as a Senior Leadership team that represents the strong functional nexus of this matrix-based Center. Dr. Kraft has charged the members of the team with employing consensus building techniques as they work directly with the various HCC boards/councils and committees to formulate priorities, strategies and allocation of resources. The Senior Leadership team works together to ensure consistency in the vision and goals of the Center;develop synergistic interactions among the basic, translational, and clinical elements of the Center;plan proactive approaches to the development of the research base and resources;effectively leverage all available resources at MUSC and at the state and national levels;engage in community outreach;and oversee all activities of the HCC. The Senior Leadership team meets several times a month in the context of HCC's various board/committee/council meetings, one-on-one with the Director, and once a month as a formal Executive Council. They provide direct counsel and recommendations to the Director based on these interactions. All final authority for decisions on behalf of the HCC resides with the Director.

Public Health Relevance

Support is requested for several members of the HCC Senior Leadership who provide counsel and recommendations to the Director as it pertains to the strategic planning and evaluation of the Center's efforts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA138313-03
Application #
8249929
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-04-01
Budget End
2012-03-31
Support Year
3
Fiscal Year
2011
Total Cost
$351,931
Indirect Cost
Name
Medical University of South Carolina
Department
Type
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Wrangle, John M; Velcheti, Vamsidhar; Patel, Manish R et al. (2018) ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol 19:694-704
Panneer Selvam, Shanmugam; Roth, Braden M; Nganga, Rose et al. (2018) Balance between senescence and apoptosis is regulated by telomere damage-induced association between p16 and caspase-3. J Biol Chem 293:9784-9800
Janakiraman, Harinarayanan; House, Reniqua P; Gangaraju, Vamsi K et al. (2018) The Long (lncRNA) and Short (miRNA) of It: TGF?-Mediated Control of RNA-Binding Proteins and Noncoding RNAs. Mol Cancer Res 16:567-579
Jin, Junfei; Lu, Zhongyang; Li, Yanchun et al. (2018) LPS and palmitate synergistically stimulate sphingosine kinase 1 and increase sphingosine 1 phosphate in RAW264.7 macrophages. J Leukoc Biol 104:843-853
Joseph, Anne M; Rothman, Alexander J; Almirall, Daniel et al. (2018) Lung Cancer Screening and Smoking Cessation Clinical Trials. SCALE (Smoking Cessation within the Context of Lung Cancer Screening) Collaboration. Am J Respir Crit Care Med 197:172-182
Rojewski, Alana M; Tanner, Nichole T; Dai, Lin et al. (2018) Tobacco Dependence Predicts Higher Lung Cancer and Mortality Rates and Lower Rates of Smoking Cessation in the National Lung Screening Trial. Chest 154:110-118
Ramshesh, Venkat K; Lemasters, John J (2018) Imaging of Mitochondrial pH Using SNARF-1. Methods Mol Biol 1782:351-356
Kim, Myung Jong; Jeon, Sohee; Burbulla, Lena F et al. (2018) Acid ceramidase inhibition ameliorates ?-synuclein accumulation upon loss of GBA1 function. Hum Mol Genet 27:1972-1988
Chatterjee, Shilpak; Chakraborty, Paramita; Daenthanasanmak, Anusara et al. (2018) Targeting PIM Kinase with PD1 inhibition Improves Immunotherapeutic Antitumor T-cell Response. Clin Cancer Res :
Jiang, Yu Lin; Zhu, Yun; Moore, Alfred B et al. (2018) Biotinylated Bioluminescent Probe for Long Lasting Targeted in Vivo Imaging of Xenografted Brain Tumors in Mice. ACS Chem Neurosci 9:100-106

Showing the most recent 10 out of 536 publications